Ziconotide
Also known as: Prialt, SNX-111
Popular For
Chronic pain management, neuropathic pain
Key Facts: Ziconotide
- Category
- Healing
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Severe chronic pain
- Administration
- Intrathecal infusion only
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- FDA Approved
- Duration
- Chronic use via intrathecal pump
Mechanism of Action
Ziconotide blocks N-type voltage-gated calcium channels (Cav2.2) in the spinal cord. This prevents neurotransmitter release from pain-signaling neurons, providing analgesia without opioid receptor involvement.
Research Summary
Effective for severe chronic pain refractory to other treatments. Studies show significant pain reduction without tolerance development. Complex delivery limits use to specialized pain centers.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Specialized intrathecal use only
Doses from Studies
0.1-19.2 mcg/day intrathecal
Slow titration required
Duration
Chronic use via intrathecal pump
Administration
Intrathecal infusion only
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Dizziness (40%)
- ●Nausea
- ●Confusion
- ●Hallucinations
- ●Depression
- ●Suicidal ideation
- ●Memory impairment
- ●BLACK BOX WARNING: Severe psychiatric symptoms
- ●FDA approved (Prialt) - intrathecal only
References
Related Peptides
Peptides commonly compared with Ziconotide or used in similar applications.
BPC-157
PreclinicalA synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
HealingTB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
HealingPentadecapeptide
PreclinicalThe full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
HealingThymosin Beta-4
Clinical TrialsThe full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
HealingSemaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Ziconotide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.